Lee G-W, Kim J-Y, Koh E-H, Kang D, Choi D S, Maeng K-Y, Lee J-S
Department of Internal Medicine, School of Medicine, Gyeongsang National University, Chilamdong, Jinju, South Korea.
Genet Mol Res. 2012 Nov 28;11(4):4034-42. doi: 10.4238/2012.November.28.2.
Different treatment outcomes and prognoses in patients with breast cancer can be observed with similar clinical predictors; this is because the biology of breast cancer is complex and heterogenous, involving multiple unknown contributing factors. We looked for plasma human mammaglobin (hMAM) mRNA by RT-PCR in 82 Korean patients with breast cancer to determine if there is an association between the presence of plasma hMAM mRNA in these patients and known prognostic factors. The prognostic usefulness of detection of plasma hMAM mRNA expression in these patients was also evaluated by determining overall survival and event-free survival. A significant difference was observed in the rate of positivity of plasma hMAM mRNA between the early stages of cancer (stages I-II, 23.4%) and advanced stages (stages III-IV, 82.9%). The expression rates of estrogen receptor, progesterone receptor, and HER-2/neu in the breast tissue of these patients, by immunohistochemistry, were 69.5, 75.6, and 20.7%, respectively. In the univariate analysis, plasma hMAM expression was significantly correlated with high histological and nuclear grades, nodal metastasis, and negative estrogen receptor and progesterone receptor status. Patients negative for plasma hMAM mRNA had significantly higher rates of event-free survival compared to the patients positive for plasma hMAM mRNA. However, no significant association with overall survival was observed for expression of plasma hMAM mRNA (P = 0.16). Qualitative detection of plasma hMAM mRNA appears to be associated with unfavorable prognostic factors and lower rates of event-free survival in patients with breast cancer.
在具有相似临床预测指标的乳腺癌患者中，可以观察到不同的治疗结果和预后；这是因为乳腺癌的生物学特性复杂且具有异质性，涉及多个未知的影响因素。我们通过逆转录聚合酶链反应（RT-PCR）在82例韩国乳腺癌患者中检测血浆人乳腺珠蛋白（hMAM）mRNA，以确定这些患者血浆中hMAM mRNA的存在与已知预后因素之间是否存在关联。还通过确定总生存期和无事件生存期来评估检测这些患者血浆hMAM mRNA表达的预后价值。在癌症早期（I-II期，23.4%）和晚期（III-IV期，82.9%）之间，观察到血浆hMAM mRNA阳性率存在显著差异。通过免疫组织化学检测，这些患者乳腺组织中雌激素受体、孕激素受体和HER-2/neu的表达率分别为69.5%、75.6%和20.7%。在单因素分析中，血浆hMAM表达与高组织学分级和核分级、淋巴结转移以及雌激素受体和孕激素受体阴性状态显著相关。与血浆hMAM mRNA阳性的患者相比，血浆hMAM mRNA阴性的患者无事件生存率显著更高。然而，未观察到血浆hMAM mRNA表达与总生存期之间存在显著关联（P = 0.16）。血浆hMAM mRNA的定性检测似乎与乳腺癌患者的不良预后因素和较低的无事件生存率相关。
